FRANKFURT, Oct 16 (Reuters) - Novartis said on

Thursday its Fabhalta drug was shown to meaningfully slow the

progression of a rare type of kidney disease under final results

of a late-stage trial.

The Swiss drugmaker said the Phase III trial data on

treating the condition known as IgA nephropathy would support a

request in 2026 for traditional U.S. regulatory market approval.